RIPK2, a cytoplasmic kinase integral to host defense, functions as a critical link between the intracellular pattern recognition receptors NOD1/NOD2 and downstream signaling cascades responsible for bacterial pathogen clearance. Despite its importance, direct modulation of RIPK2’s activity via kinase inhibition has yielded limited clinical benefit, prompting scientists to explore alternative strategies that exploit regulation at the level of protein stability rather than enzymatic activity.

The team began their exploration by screening a comprehensive panel of kinase inhibitors to identify compounds capable of inducing selective degradation of endogenous RIPK2. Among nine candidates that appeared to destabilize RIPK2, one inhibitor termed RI-4 emerged as the most potent and selective agent. In vitro binding assays confirmed direct engagement of RI-4 with recombinant RIPK2, strongly indicating a degradation mechanism linked to compound binding rather than off-target toxicity.

A key feature of RI-4-stimulated RIPK2 degradation was its reliance on protein turnover rather than transcriptional downregulation. This was convincingly demonstrated through the use of flow cytometry–based reporters and immunoblots that tracked loss of RIPK2 protein over time in human cancer cell lines engineered for inducible Cas9 expression. The selectivity of RI-4 was further validated by quantitative proteomics profiling, revealing minimal off-target degradation effects across the kinome.

To decipher the underlying cellular machinery orchestrating RI-4-promoted RIPK2 degradation, the investigators performed a genome-wide CRISPR–Cas9 knockout screen based on fluorescence-activated cell sorting. This unbiased approach uncovered a critical dependency on lysosomal degradation pathways, refuting involvement of the proteasome in this process. Several components associated with macroautophagy, including the essential autophagy mediator FIP200, were identified as indispensable for the degradation cascade, highlighting autophagy rather than proteasomal pathways as the primary route for RIPK2 clearance.

Intriguingly, pharmacological blockade of lysosome acidification using Bafilomycin A1 effectively rescued RIPK2 protein levels after RI-4 treatment, reinforcing the lysosomal degradation hypothesis. Further mechanistic studies showed that RIPK2 assembled into discrete intracellular foci or “RIPosomes” shortly after RI-4 exposure. These multimers depended on the presence of RIPK2’s caspase recruitment domain (CARD), a motif central to physiological activation of RIPK2 signaling and aggregation under stress conditions.

The RI-4–induced RIPK2 puncta exhibited dynamic clearance that was significantly inhibited when lysosomal function was disrupted. This phenomenon mirrors the cell’s natural response to microbial pathogen stimulation, reinforcing the notion that RI-4 exploits a native proteolytic circuit to promote RIPK2 turnover by mimicking infection-triggered assembly and degradation processes. Advanced live-cell microscopy and orthogonal fluorescent reporters confirmed co-localization of these higher-order complexes, giving direct visual evidence of RI-4-induced multimerization.

To characterize proteins associating with these RIPosomes, the researchers employed proximity biotinylation (BioID) proteomics over time courses capturing early and late assembly states. Gene ontology analyses enriched for ubiquitin system components revealed prominent Lys63-linked ubiquitination as a hallmark modification facilitating recognition and clearance of RIPK2 complexes. Notable interactors included deubiquitinases such as TNFAIP3 and CYLD, as well as autophagy receptor SQSTM1/p62, implicating ubiquitin-dependent selective autophagy in this degradation pathway.

Importantly, two E3 ubiquitin ligases containing inhibitor of apoptosis protein (IAP) domains—cIAP1 and XIAP—were enriched proximal to RIPK2 after RI-4 treatment. Genetic ablation of both ligases impaired degradation, demonstrating their redundant yet essential roles in tagging RIPK2 for autophagic destruction. Mutations in RIPK2 disrupting IAP binding phenocopied this effect, further substantiating the functional importance of these ligases in mediating ubiquitin-dependent turnover.

A key mediator uncovered in this study was TMUB1, a ubiquitin-like (UBL) domain-containing protein previously unlinked to RIPK2 regulation. Although TMUB1 did not surface in BioID datasets, targeted depletion experiments revealed its role as an early facilitator of RIPK2 multimerization and degradation. Loss of TMUB1 delayed RIPK2 foci formation and subsequent clearance, and biochemical assays confirmed direct drug-induced interactions between TMUB1 and RIPK2, cementing its role in the assembly process.

Collectively, these findings illustrate an elegant model in which RI-4 induces aberrant higher-order RIPK2 multimerization facilitated by TMUB1, mimicking physiological signal-induced “RIPosome” formation. This assembly is then recognized and ubiquitinated primarily via cIAP1 and XIAP ligases, designating it for macroautophagic degradation. The study reveals a nuanced modulation of kinase stability through native proteolytic circuits that can be pharmacologically exploited to reshape immune signaling.

The implications of this work extend beyond RIPK2 biology, signaling a paradigm shift by demonstrating how selective small-molecule compounds can supercharge kinase turnover rather than merely inhibiting catalytic activity. This opens fresh avenues for targeting kinases involved in a range of pathologies, particularly inflammatory and infectious diseases where controlled protein destruction may be therapeutically advantageous.

By integrating multidisciplinary approaches including chemical biology, CRISPR screening, proteomics, and advanced imaging, the research offers an unprecedented glimpse into the drug-induced remodeling of native protein homeostasis networks. Future endeavors will likely explore whether similar mechanisms apply to other cancer-relevant kinases and how this knowledge can be harnessed to design next-generation degraders with superior selectivity and efficacy.

In summary, the study illuminates a sophisticated interplay between kinase small-molecule inhibitors and cellular proteolytic systems, invigorating RIPK2 for rapid lysosomal turnover through TMUB1-facilitated multimerization and ubiquitin-dependent macroautophagy. This elegant manipulation of the cell’s intrinsic quality control machinery portends transformative possibilities for therapeutic kinase targeting strategies.

Subject of Research: RIPK2 kinase degradation and regulation via inhibitor-induced multimerization and macroautophagy.

Article Title: Inhibitors supercharge kinase turnover through native proteolytic circuits.

Article References:
Scholes, N.S., Bertoni, M., Comajuncosa-Creus, A. et al. Inhibitors supercharge kinase turnover through native proteolytic circuits. Nature (2025). https://doi.org/10.1038/s41586-025-09763-9

DOI: https://doi.org/10.1038/s41586-025-09763-9

Pyroptosis, characterized by membrane pore formation and consequent cell lysis, is primarily driven by the GSDMD protein. Under inflammatory cues, GSDMD is cleaved by inflammatory caspases, liberating its N-terminal domain that oligomerizes within the plasma membrane to form pores. These pores allow the release of inflammatory cytokines and ultimately cause cell rupture, exacerbating local and systemic inflammation. While this process is essential for antimicrobial defense, excessive or uncontrolled pyroptosis contributes to a range of inflammatory diseases, including sepsis, neurodegeneration, and autoinflammatory disorders.

The new study, conducted by Xu, Fu, Xing, and colleagues, delineates a strategy that chemically promotes the dimerization of the GSDMD C-terminal domain—an approach that effectively neutralizes the pore-forming N-terminal fragment. Unlike previous attempts to inhibit pyroptosis, which often targeted upstream inflammasome components or caspase enzymes and risked broadly suppressing immune defenses, this innovative tactic applies a more direct and targeted blockade at the effector molecule itself.

At the molecular level, the research team employed precision chemical inducers to drive dimerization of the GSDMD C-terminal domain post-cleavage. This artificially induced dimerization stabilizes the conformation of the inhibitory C-terminal segment in a manner that precludes the N-terminal domain from anchoring and oligomerizing in the membrane. This conformation shift essentially ‘traps’ the N-terminal fragment in a dormant state, preventing the formation of the lethal pores responsible for pyroptotic disruption.

Through meticulous biochemical assays and live-cell imaging, the investigators demonstrated that cells expressing the chemically dimerized GSDMD C-terminal domain exhibited profound resistance to pyroptotic stimuli. These cells showed drastically decreased membrane permeabilization, reduced inflammatory cytokine release, and enhanced survival under conditions that normally induce robust pyroptosis. This proof-of-principle experiment sets a precedent for modulating cell death pathways with engineered molecular interventions.

Crucially, the strategy leverages the dual-domain architecture unique to gasdermins, exploiting the intrinsic autoinhibitory function of the C-terminal domain, which in non-cleaved GSDMD naturally masks the pore-forming capacity of the N-terminal domain. By pharmacologically mimicking this natural autoinhibition post-cleavage, the approach offers a level of specificity and reversibility that could be fine-tuned for therapeutic gain.

The implications of this work extend far beyond the laboratory bench. The ability to selectively target GSDMD pore formation points to a new class of anti-inflammatory therapeutics that may prevent tissue damage in conditions exacerbated by pyroptosis. Diseases such as septic shock, inflammatory bowel disease, and even certain neurodegenerative syndromes, all marked by aberrant pyroptotic activity, could benefit from treatments developed from this novel molecular insight.

Moreover, this chemically induced dimerization approach may serve as a valuable tool to dissect the precise kinetics and regulation of gasdermin-mediated pyroptosis in various physiological contexts. By controlling the dimerization state of the C-terminal domain, researchers can now finely manipulate pyroptotic thresholds, further elucidating the balance between protective inflammation and pathological damage.

While these findings illuminate a promising new horizon in cell death modulation, challenges remain for translating this discovery into clinical interventions. Key among these is the development of safe, bioavailable chemical inducers capable of penetrating relevant tissues and selectively targeting GSDMD in vivo without impairing the essential functions of the innate immune system.

Nevertheless, the innovative concept of harnessing chemically induced structural changes within gasdermin molecules introduces an unprecedented therapeutic paradigm. It shifts the focus from upstream inflammasome inhibition to direct modulation of the terminal executioner of pyroptosis, offering enhanced specificity and potentially fewer side effects.

In addition to therapeutic prospects, the deeper understanding gained from this study enriches fundamental cell biology. It provides concrete evidence of the structure-function relationship within GSDMD domains and showcases how molecular interactions can be harnessed or disrupted to alter cellular fate decisively.

The experimental design included a combination of structural biology techniques, live-cell functional assays, and advanced fluorescence imaging. These methods collectively confirmed that chemical dimerizers lock the C-terminal domain in a conformation that inhibits the N-terminal domain’s ability to insert into lipid bilayers, thereby blocking the hallmark membrane permeabilization of pyroptosis.

Furthermore, the research emphasized the importance of targeting the C-terminal domain as a therapeutic entry point. Since this domain remains associated with the N-terminal fragment following proteolytic cleavage, its manipulation via chemical dimerization presents a practical avenue for drug design that circumvents the complexity of targeting multiple inflammasome components.

This strategy’s potential for broad application is underscored by the conserved nature of GSDMD-mediated pyroptosis across diverse cell types and species. As such, therapeutic agents based on this concept could address a spectrum of inflammatory diseases that share pyroptotic pathology.

Looking forward, the integration of this molecular dimerization approach with targeted delivery systems, such as nanocarriers or tissue-specific ligands, could provide precision medicine options. Such advances may enable localized suppression of pyroptosis without systemic immune compromise, thereby enhancing patient safety profiles.

In sum, the discovery articulated by Xu and collaborators signifies a milestone in the field of inflammatory cell biology. By chemically inducing dimerization of the GSDMD C-terminal domain, they have mapped a precise ‘off switch’ for pyroptosis, unlocking new opportunities for therapeutic intervention and expanding the toolkit for understanding apoptosis-like programmed cell death mechanisms.

As the scientific community builds on this foundational insight, we can anticipate the rapid evolution of pyroptosis-targeted therapies and novel diagnostic tools that harness the molecular intricacies of gasdermin regulation. The future of inflammatory disease treatment appears poised for significant transformation, rooted in this elegant molecular engineering feat.

Subject of Research: Molecular mechanisms regulating pyroptosis via Gasdermin D

Article Title: Chemically induced dimerization of GSDMD C-terminal domain blocks GSDMD N-terminal domain-mediated pyroptosis

Article References:
Xu, J., Fu, M., Xing, Y. et al. Chemically induced dimerization of GSDMD C-terminal domain blocks GSDMD N-terminal domain-mediated pyroptosis. Cell Death Discov. 11, 456 (2025). https://doi.org/10.1038/s41420-025-02733-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02733-0